End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.73 USD | +4.27% | +24.84% | +100.35% |
Apr. 24 | Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis | CI |
Apr. 01 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 61.54M |
---|---|---|---|---|---|
Net income 2024 * | -26M | Net income 2025 * | -35M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.5
x | P/E ratio 2025 * |
-2.6
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.09% |
1 day | +4.27% | ||
1 week | +24.84% | ||
1 month | +37.74% | ||
3 months | -22.98% | ||
6 months | +160.45% | ||
Current year | +100.35% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 5.73 | +4.27% | 19,710 |
24-04-29 | 5.495 | +0.83% | 15,627 |
24-04-26 | 5.45 | +3.02% | 8,939 |
24-04-25 | 5.29 | -3.64% | 18,095 |
24-04-24 | 5.49 | +19.61% | 76,715 |
End-of-day quote Nasdaq, April 29, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+100.35% | 59.02M | |
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |
- Stock Market
- Equities
- CALC Stock